The shares of Zosano Pharma Corporation (NASDAQ: ZSAN) rose 33.6% to $2.58 in pre-market trade following a strong jump at the prior close. The performance of ZSAN over the same period last year has been 266.15%. Stock price charts for the past seven days show an increase of 96.94% over the past week and 147.47% over the past month.
What is the latest Update?
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The company’s most recent update came on the first day of this month when Zosano Pharma Corporation (NASDAQ: ZSAN) announced patient outcomes from an early onset of action study for Qtrypta, Zosano’s investigational treatment for acute migraines. The study used Zosano’s microneedle system.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
We consider Qtrypta to be an attractive therapeutic alternative to acutely treat migraines,” says Steven Lo, founder and CEO of Zosano. Qtrypta has demonstrated rapid pain relief in patients who are nauseated and rarely able to take oral medications that take time to pass through the digestive tract until pain relief is achieved.
82 subjects who received Qtrypta had pain relief at 30 minutes, and 28 of the 38 subjects were pain-free at two hours (74%) after receiving Qtrypta. The data were analyzed retrospectively in a previous study published in the Journal of Pain Treatment. Two hours after Qtrypta treatment, all six subjects who reported pain freedom at 30 minutes were pain-free. It compares to nine of 26 subjects (35%) in the placebo group (n=77) who reported pain relief at 30 minutes who were pain-free at 2 hours, and one of two subjects who were pain-free at 30 minutes to be pain-free at 2 hours.
These data describe a reduction in migraine frequency and intensity at 30 minutes, consistent with criteria for assessing treatment efficacy published in Cephalalgia, an International Headache Journal, by Pfelt-Hansen and Diener. It suggests that the post-hoc analysis of data from the ZOTRIP trial could point in the direction of the therapeutic gain in terms of pain freedom, instead of pain relief, as a more reliable endpoint for assessing the rapid onset of action.
Investors are surely closely following the recommendations of analysts on Wall Street regarding Zosano Pharma Corporation (NASDAQ: ZSAN). Based on current estimates, analysts rate ZSAN as a Buy. An average rating of 2.00 is assigned to the stock with a simple range of 1 to 5. Between 0 and 2 indicates a Buy recommendation whereas the value in the range of 2 to 3 suggests a Hold whereas the value above 3 suggests that the investors should Sell the stock. Presently, the stock has a Buy recommendation from 2 Wall Street analysts.